RxDoctor Payments Data

Phillip Schirck, MD

Internal Medicine · Hamlin, NYNPI 1447286307

Payments from drug & device makers

$7,273in general payments, 2019–2025

Across 413 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$1K
  • GSK$1K
  • AbbVie$724
  • Novo Nordisk$659
  • Lilly USA, LLC$599
  • plus $2K from 16 others

What the payments were for

  • Food & beverage$7,262100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,273 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$52,780
Medicare patients
57
Services billed
719

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide77$92,487
TrulicityDulaglutide64$68,401
JardianceEmpagliflozin60$64,644
CreonLipase/Protease/Amylase22$57,625
VraylarCariprazine Hcl34$49,588
EliquisApixaban51$45,277
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$39,311
EntrestoSacubitril/Valsartan32$30,986
XareltoRivaroxaban21$23,926
FarxigaDapagliflozin Propanediol25$21,640
JanuviaSitagliptin Phosphate13$20,389
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$15,435
MounjaroTirzepatide11$11,569
Lantus SolostarInsulin Glargine,hum.Rec.Anlog60$8,488
Albuterol Sulfate HfaAlbuterol Sulfate138$5,992

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Vraylar$724$107,21356 claims
Novo NordiskOzempic$659$92,48777 claims
Lilly USA, LLCTrulicity, Mounjaro$599$79,97075 claims
Boehringer IngelheimJardiance$178$64,64460 claims
PfizerEliquis$1,038$45,27751 claims
GSKTrelegy Ellipta$1,013$39,31145 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,476$37,07542 claims
NovartisEntresto$180$30,98632 claims
Johnson & JohnsonXarelto$393$23,92621 claims
MerckJanuvia$64$20,38913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hamlin

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →